



**QUEEN'S
UNIVERSITY
BELFAST**

Novel grading system for quantification of cystic macular lesions in Usher syndrome

Sliesoraityte, I., Peto, T., Mohand-Said, S., & Sahel, J. A. (2015). Novel grading system for quantification of cystic macular lesions in Usher syndrome. *Orphanet journal of rare diseases*, 10, [157]. DOI: 10.1186/s13023-015-0372-0

Published in:

Orphanet journal of rare diseases

Document Version:

Publisher's PDF, also known as Version of record

Queen's University Belfast - Research Portal:

[Link to publication record in Queen's University Belfast Research Portal](#)

Publisher rights

Copyright 2015 The Authors.

This is an open access article published under a Creative Commons Attribution License (<https://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution and reproduction in any medium, provided the author and source are cited.

General rights

Copyright for the publications made accessible via the Queen's University Belfast Research Portal is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy

The Research Portal is Queen's institutional repository that provides access to Queen's research output. Every effort has been made to ensure that content in the Research Portal does not infringe any person's rights, or applicable UK laws. If you discover content in the Research Portal that you believe breaches copyright or violates any law, please contact openaccess@qub.ac.uk.

RESEARCH

Open Access



Novel grading system for quantification of cystic macular lesions in Usher syndrome

Ieva Sliesoraityte^{1*}, Tunde Peto², Saddek Mohand-Said¹ and Jose Alain Sahel^{1,3}

Abstract

Background: To evaluate novel grading system used to quantify optical coherence tomography (OCT) scans for cystic macular lesions (CML) in Usher syndrome (USH) patients, focusing on CML associated alterations in *MYO7A* and *USH2A* mutations.

Methods: Two readers evaluated 76 patients' (mean age 42 ± 14 years) data prospectively uploaded on Eurush database. OCT was used to obtain high quality cross-sectional images through the fovea. The CML was graded as none, mild, moderate or severe, depending on the following features set: subretinal fluid without clearly detectable CML boundaries; central macular thickness; largest diameter of CML; calculated mean of all detectable CML; total number of detectable CML; retinal layers affected by CML. Intra- and inter-grader reproducibility was evaluated.

Results: CML were observed in 37 % of USH eyes, while 45 % were observed in *MYO7A* and 29 % in *USH2A* cases. Of those with CML: 52 % had mild, 22 % had moderate and 26 % had severe changes, respectively. CML were found in following retinal layers: 50 % inner nuclear layer, 44 % outer nuclear layer, 6 % retinal ganglion cell layer. For the inter-grader repeatability analysis, agreement rates for CML were 97 % and kappa statistics was 0.91 (95 % CI 0.83-0.99). For the intra-grader analysis, agreement rates for CML were 98 %, while kappa statistics was 0.96 (95 % CI 0.92-0.99).

Conclusions: The novel grading system is a reproducible tool for grading OCT images in USH complicated by CML, and potentially could be used for objective tracking of macular pathology in clinical therapy trials.

Keywords: Cystic macular lesions, Grading system, Optical coherence tomography, Usher syndrome, Genotype, Phenotype

Background

Usher syndrome (USH) is a rare autosomal recessive group of disorders characterized by retinitis pigmentosa (RP), sensorineural hearing loss and vestibular dysfunction. Three clinical types are distinguished (USH1, USH2 and USH3) and additional atypical subtypes have been described associated with 10 causative genes and three additional loci [1–5]. Hearing impairment is a first symptom to develop in USH. Visual symptoms manifest as retinitis pigmentosa (RP), a progressive retinal dystrophy, with rod and secondary cone photoreceptor dysfunction and ultimate loss. USH is a clinically and genetically heterogeneous disorder, making diagnosis and treatment challenging [6–9]. Previous studies categorized the

morphological retinal findings of USH patients, showing that cystoid macula edema and/or cystic macular lesions (CML) are the most common complications in RP associated with USH (USH-RP) [10, 11]. CML has been reported to be present in 8-56 % of all USH and/or RP patients [12–19].

Morphologically CML is characterized as a focal or generalized retinal thickening due to accumulation of fluid within retinal layers, which may lead to the formation of a lamellar or full-thickness macular hole. Moreover, even non-significant cystoid changes might contribute to a progressive impairment of visual acuity in RP, likely due to the degenerative process affecting retinal layers [20]. The central macula thickness (CMT) is assumed to be a potential morphological end-point for evaluating safety and efficacy of a treatment modality, which is aimed primarily for improving macular photoreceptor cells associated structure

* Correspondence: isliesoraityte@gmail.com

¹Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts, DHU Sight Restore, INSERM-DHOS CIC 1243, 28 rue de Charenton, 75012 Paris, France
Full list of author information is available at the end of the article

and/or function. Thus, it is of a key importance to have a sophisticated grading system for quantification of CML in USH-RP associated with CML.

Even though CML is a frequent complication of RP and despite of several attempts to grade CML [21, 22], a need remains for an image grading protocol based on optical coherence tomography (OCT) to assist clinicians in describing all relevant aspects of an individual type of CML in USH-RP cases. We propose a new CML grading system for USH-RP patients, including comparative evaluation of CML between USH types and most frequent USH-associated genes, i.e. *MYO7A* and *USH2A*. Such a grading system would allow evaluation of USH-RP prognostic factors and treatment decisions in a very detailed way.

Methods

Subjects and database

This prospective observational cohort study was conducted according to the tenets of the Declaration of Helsinki and received authorization from Ile-de-France V ethical board committee for human research (June 4th 2013) and from the French regulation agency for medication (September 3rd 2013) (<http://clinicaltrials.gov/ct2/show/NCT01954953>). The Eurush database (www.eurush-database.org) was used where subjects' data were uploaded on a prospective manner. The participants were recruited at the Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts, Paris, France. The study procedure was fully explained to all patients, and their informed written consent was obtained. Seventy six patients with a clinical diagnosis of USH were enrolled (age 42 ± 14 years). The inclusion criteria were: clinical characteristics for USH1, USH2 and USH3 as defined by the Usher syndrome consortium [23]; informed consent and agreement to participate in the study. Exclusion criteria were: systemic pathologies or severe ocular pathologies; systemic or topical medication usage; otolaryngology pathologies which could contaminate the results; unwillingness to provide a blood sample for genetic test; unwilling and/or unable to undergo the study procedures. In more details we analyzed two groups, i.e. having mutations in genes *USH2A* and *MYO7A*.

Each patient underwent standard comprehensive ophthalmological examinations, which included assessment of the medical and family history, best corrected visual acuity (BCVA) using *Early Treatment Diabetic Retinopathy Study* (EDTRS), tonometry, slit-lamp biomicroscopy, direct and indirect ophthalmoscopy, static and kinetic perimetry using standard III4e isopters (Haag Streit, Koeniz, Switzerland). Full-field electroretinography (ERG) was performed with the Espion system (Espion Diagnosys, Littleton, MA), whereas multifocal electrophysiological recordings were carried out using the VERIS 4.9.1 system

(Electro-Diagnostic Imaging, Inc., Redwood City). OCT and fundus autofluorescence (AF) were carried out using HRA II confocal scanning laser ophthalmoscope (Heidelberg Engineering, Heidelberg, Germany).


Standard cystic macular lesions grading procedure

OCT image grading was performed in XV/XX reading centre (Paris, France). High quality macula scans were acquired using Spectralis HRA + OCT (Heidelberg Engineering, Dossenheim, Germany). The macular acquisition protocol consisted of 19 line raster fovea centered scans with at least a 15° by 15° region. The standard file transfer protocol was employed to transfer images in anonymous format to a local server. Five single scans lines, i.e. foveal scan, two below and two above the fovea were used for determining CML in both eyes. Both eyes were checked for CML. Only one (right) eye high quality cross-sectional image through the fovea was used for further grading. If CML were not present in foveal line scan but appeared in other 2 lines below or above the fovea, the closest line to the fovea was used for grading.

The trained graders performed OCT image grading using a novel grading system for CML quantification. In addition, 3 randomly selected tomograms were provided to each grader to test reproducibility. All reproducibility testing were performed 5 weeks after initial grading to avoid possible reader recall of the initial arbitration and to monitor temporal variability. The intra-grader and inter-grader reproducibility was calculated, in details described elsewhere [24]. Scan quality was estimated depending on presence/absence following features: fovea non determinable on OCT, incorrect positioning, and very poor saturation due to cataract and/or vitreous strands and opacities.

The protocol used to define the CML included the presence of cystoids spaces defined as hypo-reflective zone visible on at least two views of the sequential line scans in macula area. The boundaries of each CML were manually marked using Adobe Photoshop CS5.5 version. A grading protocol was defined covering all possible morphological alterations and characteristic patterns typically associated with CML, namely: 1. Subretinal fluid without clearly detectable CML boundaries (F_s); 2. CMT; 3. Largest diameter of CML (D_n); 4. Calculated mean of all detectable CML (D); 5. Total number of detectable CML (N); 6. Retinal layers affected by CML (L) (Fig. 1). Hence, CML was graded as mild, moderate or severe depending on above described features pattern (Table 1).

Currently, there is no available standard CML grading system and CMT is used for edema evaluation. Only for comparative reasons with the literature data, we extinguished CMT criterion from CML grading system for the more detailed analysis. Once the grading database



was verified and closed, the grading and clinical data were merged for the analysis.

Statistical analysis

Statistical analysis was carried out using SPSS software (version 19.0, SPSS Inc., Chicago, USA). We analyzed CML in the whole cohort and in two groups associated with mutations in *USH2A* and *MYO7A*. Pearson correlation (r) was used to assess the correlation between central macular thickness and age in a whole cohort and associated genes, namely *USH2A* and *MYO7A*. One-way

analysis of variance (ANOVA) was performed to detect differences between CML severity in associated gene *USH2A* and *MYO7A*. The percent agreement and the kappa statistics were calculated as measures for categorical variables (quality of scan and presence of CML). Percent agreement was computed as the number of concordant grading pairs divided by the total number of grading pairs multiplied by 100. All numerical data are presented here as arithmetic means ± standard deviation (SD). A two side P value less than 0.05 was considered statistically significant.

Table 1 The grading system for the cystic macular lesions severity and selected tomograms examples in Usher syndrome patients. A-B Mild: the right eye of 26 year male with mutation in *USH2A*:c.7595-3C > G+ c.7595-2144A > G, having less than 10 small size cystic lesions and central macula thickness (CMT) within 200 μm (A), the right eye of 38 year male with mutation in *USH2A*: E767fs, having less than 10 medium size cystic lesions (B); C-D Moderate: the right eye of 14 year female with mutation in *MYO7A*: L2186P *2, having more than 10 medium size cystic lesions and CMT up to 300 μm (C), the right eye of 31 year male with mutation in *USH2A*:T4337M + C717G, having up to 20 small and up to 10 medium size cystic lesions and one large diameter cyst (D); E-F severe: the right eye of 35 year female with mutation in *USH2A*:V218E + G660R, having more than 10 medium size cystic lesions, more than 5 large and several extra large (E), the right eye of 24 year male with mutation in *MYO7A*:N1182K*2, having several extra large diameter cystic lesion (F). * The presence of epiretinal membrane

Mild	Moderate	Severe
<ul style="list-style-type: none"> Retinal layer swelling, central macula thickness (CMT) <200μm, without clear cystic lesions borders and/or number of <10 small size cysts averaged $D < 50 \mu m$ and/or number of <5 medium size cysts averaged $D [50-100\mu m]$ and no large size $D [100-300\mu m]$ or extra large size cysts averaged $D > 300\mu m$. 	<ul style="list-style-type: none"> Retinal layer swelling, CMT 200-300 μm, without clear cystic lesions borders and/or number of [10-20] small size cysts averaged $D < 50 \mu m$ and/or number of [5-10] medium size cysts averaged $D [50-100\mu m]$ and/or number of <5 large size cysts averaged $D [100-300\mu m]$ and no extra large size cysts averaged $D > 300\mu m$. 	<ul style="list-style-type: none"> Retinal layer swelling, CMT ≥300 μm, without clear cystic lesions borders and/or number of ≥20 small size cysts averaged $D < 50 \mu m$ and/or number of ≥10 medium size cysts averaged $D [50-100\mu m]$ and/or number of ≥ 5 large size cysts averaged $D [100-300\mu m]$ and/or extra large size cysts averaged $D > 300\mu m$.
<p>(A)</p> <p>(B)</p>	<p>(C)</p> <p>(D)</p>	<p>(E)</p> <p>(F)</p>

Results

Main clinical characteristics

Our cohort consisted of 76 patients, 41 (54 %) were males. All 76 (100 %) patients were found to carry at least one mutation, while 68/76 (89 %) of them carrying two mutations in USH-associated genes. The methodology used to detect mutations (complete exon sequencing) in USH associated genes is described in details elsewhere [2]. The prevalence of mutations in USH-associated genes was as following: 13/76 (17 %) *MYO7A*, 4/76 (5 %) *CDH23*, 2/76 (3 %) *PCDH15*, 1/76 (1 %) *USH1C*, 44/76 (58 %) *USH2A*, 8/76 (11 %) *VLGR1*, 3/76 (4 %) *CLRN1*, and 1/76 (1 %) had mutations in *VLGR1* and *MYO7A* genes. The mean age was of 42 ± 14 years (range of 14 to 74 years). There was no statistically significant difference in age between *MYO7A* and *USH2A*: 41 ± 15 (14 to 69) years for *MYO7A* and 44 ± 13 (23 to 74) years for *USH2A*. The average BCVA for the whole cohort was 0.40 logMAR units (range, -0.1 to 1.5, Snellen equivalent of 20/50), while 0.61 logMAR units (range 0.1 to 1.5, Snellen equivalent of 20/80) for *MYO7A* and 0.34 logMAR units (-0.1 to 1.5, Snellen equivalent of 20/40) for *USH2A*. *MYO7A* patients tended to have worse BCVA compared to *USH2A*, although the difference did not reach statistically significant level ($p > 0.05$).

Grading of optical coherence tomography scans

The OCT scans were graded using the novel CML grading system (Table 1). Of the 76 USH patients, for 13 patients OCTs were not performed due to the advanced stages of USH affecting the ocular media: 2/13 (15 %) in *MYO7A*, 6/13 (46 %) in *USH2A*, and 5/13 (39 %) in other genes. Of those with performed OCT, CML were present in 23/63 (37 %) cases. CML were found in 12/23 (52 %) males and 11/23 (48 %) females, without any evident gender preponderance. We observed that USH1 (and *MYO7A*) tend to have higher incidence of CML compared to USH2 (and *USH2A*): 6/14 (43 %) in USH1 (and 5/11 (45 %) in

MYO7A) and 14/45 (31 %) in USH2 (and 11/38 (29 %) in *USH2A*), respectively. The CML severity for a USH cohort was as following: 12/23 (52 %) mild, 5/23 (22 %) moderate, and 6/23 (26 %) severe. USH1 (and *MYO7A*) tend to have more severe CML, while USH2 (and *USH2A*) tend to have mild CML (Fig. 2a and b).

Analyzing retinal layers integrity, CML tended to affect one retinal layer: 16/23 (70 %) monolayer vs 7/23 (30 %) poly-layer ($p < 0.05$). Of those with monolayer involvement, the inner nuclear layer (INL) was affected in 8/16 (50 %), outer nuclear layer (ONL) in 7/16 (44 %), and the retinal ganglion cell layer (RGC) 1/16 (6 %) cases. Of those with poly-layer involvement, the INL was affected in 6/7 (86 %), ONL in 7/7 (100 %), RGC 2/7 (29 %) and the inner plexiform layer (IPL) was affected in 2/7 (29 %) cases. There was no statistically significant difference in CML retinal layers predisposition between USH types or USH-associated genes (Fig. 3a and b). When study cohort was divided in four groups, those with monolayer CML, i.e. in RGC, INL, ONL, and poly-layer CML, the mean CMT was as following: 176 μ m (RGC), 218 ± 57 μ m (INL), 166 ± 52 μ m (ONL), and 332 ± 106 μ m (poly-layer), respectively. The more severe CML were observed in cases affecting INL compared to other layers ($p < 0.001$).

CMT values tend to be higher in *MYO7A* group compared to *USH2A*: 263 ± 91 μ m and 212 ± 89 μ m, respectively, however this was not statistically significant. Linear regression analysis showed a statistically significant association between CMT and age (at the time of examination) in USH1 and USH2 ($r = -0.51$, $p = 0.01$ and $r = -0.47$, $p = 0.01$) and as following *USH2A* and *MYO7A* ($r = -0.58$, $p = 0.01$ and $r = -0.44$, $p = 0.01$). (Fig. 4a and b).

Quality assurance data for a novel grading system

The evaluation of the proposed system is done using Eurush database estimating intra-grader and inter-grader repeatability. The time to grade one tomogram with




Fig. 2 The prevalence of cystic macular lesions severity in Usher syndrome cases. The prevalence of cystic macular lesions in USH 1 and USH 2 **a**, the prevalence of cystic macular lesions in *USH2A* and *MYO7A* **b**




Fig. 3 Cystic macular lesions distribution by retinal layers distribution in Usher syndrome cases. The prevalence of CML by affected retinal layers in USH1 vs USH2 **a**, the prevalence of CML by affected retinal layers in USH2A vs MYO7A **b**

CML required in averaged 5 min ± 1 min for the first and 6 min ± 1 min for the second grader (not statistically significant $p > 0.05$). The difference in mean CML diameter was 2 μm ± 1.5 μm between the two graders performed grading of OCT scans. Reproducibility rates were high for the categorical variables scan quality at the fovea and CML. For the inter-grader repeatability analysis, agreements rates were 97 % (95 % CI 0.915-1.00) and 95 % (95 % CI 0.89-1.00) for the scan quality at the

fovea and CML, respectively. The kappa statistics was 0.93 (95 % CI 0.85-1.00) and 0.91 (95 % CI 0.83-0.99) for the scan quality at the fovea and CML, respectively. For the intra-grader analysis, agreement rates were 96 % (95 % CI 0.80-1.00) and 98 % (95 % CI 0.89-1.00) for the scan quality at the fovea and CML, respectively. Likewise, kappa statistics was 0.91 (95 % CI 0.80-0.95) and 0.96 (95 % CI 0.92-0.99) for the scan quality at the fovea and CML, respectively.




Fig. 4 The linear regression analysis between age and central macula thickness in all Usher cohort. The statistically significant negative association was observed between CMT and patient age both in USH1 and USH2: $r = -0.51$ and $r = -0.47$ **a**; and as following in *USH2A* and *MYO7A*: $r = -0.58$ and $r = -0.44$ **b**

Discussion

In the present study, we established a novel grading system that showed to be reliable and reproducible in our reading centre for evaluating CML in USH-RP patients. Our system consists of CML detection assessed by trained graders, followed by evaluation of CML severity and assessment of affected retinal layers. Using the novel grading system OCT scans can be graded in a standard manner in about 5 minutes.

To the best of our knowledge, there are limited references in the literature regarding how to evaluate CML severity in USH-RP cases. We found that using our standard method, CML quantification gives a detailed view on retinal morphological changes which is crucial for disease progression monitoring and exact end-points estimation. In addition, the incidence of CML was compared within the most frequent USH-associated genes, i.e. *MYO7A* and *USH2A*. In our cohort of 76 USH patients, CML rate was found to be 37 %, while in *MYO7A* was of 45 % and *USH2A* was of 29 %. Almost half of *MYO7A* cases were associated with CML, although a statistically significant difference between *MYO7A* and *USH2A* groups was not reached. In addition, *MYO7A* cases tend to represent by severe CML, while *USH2A* tend to have mild CML. So far no pathophysiological studies were performed analyzing CML incidence differences in *USH2A* vs *MYO7A*. Thus, it definitely requires more detailed investigations.

Our findings of 37 % having CML in OCT scans are comparable to Hajali et al's, namely 35 % USH2 and 39 % autosomal recessive RP patients had CML in OCT scans [25, 26]. It must be acknowledged that there is a great difference in the incidence of CML among the various cohorts of RP patients, ranging from 8-15 % [12, 16, 17] to 25-56 % [14, 15, 19, 25]. One reason might be that ascertaining CML might vary due to race and ethnicity differences. CML incidence rates are highly

dependent on RP inheritance pattern (recessive, dominant or X linked) and so genotypic preponderance can also influence the results [11]. Some studies were very small which can also lead to unstable estimates. Finally, the lack of structured grading might also make ascertaining CML difficult and unreliable.

In the current study we showed that eyes with CML have 30 % greater CMT ($235 \pm 98 \mu\text{m}$) compared to those without CML ($164 \pm 59 \mu\text{m}$). Gorovoy et al. [20] also reported similar findings: 28 % of RP patients had CML and half of them had increased central foveal thickness ($239 \pm 10 \mu\text{m}$). Some differences could be explained by differences in age between studies and the variability in disease stage, in particularly the presence of retinal atrophic changes. Our study clearly showed that younger patients tended to have higher rates of CML ($r = -0.47$, $p = 0.01$). In a large enough cohort, multiple regression analysis where CML severity could be tested against age and CMT would potentially provide new insight into the natural disease history.

Additionally, we showed that CML tended to be present in INL (50 %) and ONL (44 %). Makiyama et al. [18] showed 27 % incidence of CML, while cystic lesions were observed in the same layers as in our study, namely INL (99 %) and ONL (28 %) and a minority in RGC. Fakin et al. [19] observed 56 % CML in USH-RP patients, while CML were distributed in INL (60 %), INL and ONL (33 %) and OPL (7 %). To the best of our knowledge, there was no pathophysiological studies performed so far analyzing CML affinity for the particular retinal layers.

The natural course of CML associated with RP is incompletely understood with several theories proposed. Heckenlively et al. [26] proposed that CML might be a result of an autoimmune process. The high incidence of CML in INL and ONL could be explained by microglial cells activation as a result of the autoimmune process

[27 - 29]. An alternative hypothesis could be that CML is a result of a breakdown in the retinal barrier at the level of the retinal pigment epithelium which leads to a fluid leakage in the macula. The breakdown of blood-retinal barrier potentially results in accumulation of plasma proteins which exert a high oncotic pressure in the neural interstitium, which tends to produce interstitial edema [30–32]. It is possible that both mechanisms occur together [33, 34]. Lastly, it is possible that the “cystic spaces” are actually due to apoptosis and therefore simply represent a space left from tissue loss [35].

Conclusion

A standard OCT-based retinal image evaluation in USH-RP represents an urgent need both for clinicians and scientists and calls for a reading centers focused of OCT evaluation. The proposed grading system supplies a reproducible tool for CML quantification in USH-RP, and eventually could be used for objective tracking of macular pathology in clinical trials. Using our grading system we observed that CML is a common retinal complication in USH-RP and showed that CML tended to be present in both inner and outer nuclear layer. Moreover, we found that *MYO7A* cases tend to have a higher CML incidence rate and more severe CML compared to *USH2A*.

We describe for the first time a novel grading system for CML evaluation that is based on expert knowledge and requires trained personnel. In the future, the novel grading system might be applied using semi-automatic image analysis for CML severity grading, taking into account functional and/or other significant structural measures [36–40]. The system has a potential to be implemented in reading centers as a sophisticated tool for retinal structure evaluation in USH-RP. Surely, it would be directly applicable to any CML in other retinal diseases (e.g. diabetic retinopathy, age related macula edema) and aid treatment challenges in other rare retinal degenerations.

Abbreviations

CML: cystic macular lesions; OCT: optical coherence tomography; RP: retinitis pigmentosa; USH: usher syndrome; USH-RP: retinitis pigmentosa associated with USH.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

IS and JAS designed the study protocol. IS, SMS, JAS recruited and/or evaluated patients. IS, TP, JAS developed protocol for cystic macular lesions evaluation. IS and TP implemented the statistical analysis. IS wrote manuscript, and all co-authors participated in the manuscript review. All authors read and approved the final manuscript.

Acknowledgment

The project is supported by the by national funding organizations of France (ANR), Germany (BMBF), Netherlands (ZonMW), Portugal (FCT) under the frame E-RARE 2, the ERA-Nett for Research on Rare Diseases *ERARE1 N°58: Eur-USH*, <http://eur-ush.eu>, <http://www.e-rare.eu>. TP is funded by NIHR BMRC at MEH and IoO, London, UK.

Author details

¹Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts, DHU Sight Restore, INSERM-DHOS CIC 1243, 28 rue de Charenton, 75012 Paris, France. ²NIHR Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, 162 City Road, EC1V 2PD London, UK. ³INSERM, CNRS, Institut de la Vision, Sorbonne Universités, UPMC Univ Paris 06, 17 rue Moreau, 75012 Paris, France.

Received: 26 June 2015 Accepted: 25 November 2015

Published online: 10 December 2015

References

- Sahel J, Bonnet S, Mrejen S, Paques M. Retinitis pigmentosa and other dystrophies. *Dev Ophthalmol*. 2010;47:160–7.
- Bonnet C, Grati M, Marlin S, Levilliers J, Hardelin JP, Parodi M, et al. Complete exon sequencing of all known Usher syndrome genes greatly improves molecular diagnosis. *Orphanet J Rare Dis*. 2011;6:21.
- Vaché C, Besnard T, Le Berre P, García-García G, Baux D, Larrieu L, et al. Usher syndrome type 2 caused by activation of an *USH2A* pseudoexon: implications for diagnosis and therapy. *Hum Mutat*. 2012;33(1):104–8.
- Aparisi MJ, Aller E, Fuster-García C, García-García G, Rodrigo R, Vázquez-Manrique RP, et al. Targeted next generation sequencing for molecular diagnosis of Usher syndrome. *Orphanet J Rare Dis*. 2014;9:168.
- Blanco-Kelly F, Jaijo T, Aller E, Avila-Fernandez A, López-Molina MI, Giménez A, et al. Clinical Aspects of Usher Syndrome and the *USH2A* Gene in a Cohort of 433 Patients. *JAMA Ophthalmol*. 2015;133(2):157–64.
- Kremer H, Van Wijk E, Märker T, Wolfrum U, Roepman R. Usher syndrome: molecular links of pathogenesis, proteins and pathways. *Hum Mol Genet*. 2006;15(2):R262–70.
- Sandberg MA, Brockhurst RJ, Gaudio AR, Berson EL. Visual acuity is related to parafoveal retinal thickness in patients with retinitis pigmentosa and macular cysts. *Invest Ophthalmol Vis Sci*. 2008;49:4568–72.
- Yang J, Wang L, Song H, Sokolov M. Current understanding of usher syndrome type II. *Front Biosci*. 2012;17:1165–83.
- Västinsalo H, Jalkanen R, Bergmann C, Neuhaus C, Kleemola L, Jauhola L, et al. Extended mutation spectrum of Usher syndrome in Finland. *Acta Ophthalmol*. 2013;91(4):325–34.
- Johnson MW. Etiology and treatment of macular edema. *Am J Ophthalmol*. 2009;147:11–21.
- Testa F, Rossi S, Colucci R, Gallo B, Di Iorio V, Della Corte M, et al. Macular abnormalities in Italian patients with retinitis pigmentosa. *Br J Ophthalmol*. 2014;98(7):946–50.
- Hirakawa H, Iijima H, Gohdo T, Tsukahara S. Optical coherence tomography of cystoid macular edema associated with retinitis pigmentosa. *Am J Ophthalmol*. 1999;128(2):185–91.
- Apushkin MA, Fishman GA, Janowicz MJ. Monitoring cystoid macular edema by optical coherence tomography in patients with retinitis pigmentosa. *Ophthalmology*. 2004;111:1899–904.
- Adackapara CA, Sunness JS, Dibernardo CW, Melia BM, Dagnelie G. Prevalence of cystoid macular edema and stability in oct retinal thickness in eyes with retinitis pigmentosa during a 48-week lutein trial. *Retina*. 2004;28(1):103–10.
- Walia S, Fishman GA, Hajali M. Prevalence of cystic macular lesions in patients with Usher II syndrome. *Eye (Lond)*. 2009;23(5):1206–9.
- Hagiwara A, Yamamoto S, Ogata K, Sugawara T, Hiramatsu A, Shibata M, et al. Macular abnormalities in patients with retinitis pigmentosa: prevalence on OCT examination and outcomes of vitreoretinal surgery. *Acta Ophthalmol*. 2011;89:122–5.
- Triolo G, Pierro L, Parodi MB, De Benedetto U, Gagliardi M, Manitto MP, et al. Spectral domain optical coherence tomography findings in patients with retinitis pigmentosa. *Ophthalmic Res*. 2013;50(3):160–4.
- Makiyama Y, Oishi A, Otani A, Ogino K, Nakagawa S, Kurimoto M, et al. Prevalence and spatial distribution of cystoid spaces in retinitis pigmentosa: investigation with spectral domain optical coherence tomography. *Retina*. 2014;34(5):981–8.
- Fakin A, Jarc-Vidmar M, Glavač D, Bonnet C, Petit C, Hawlina M. Fundus autofluorescence and optical coherence tomography in relation to visual function in Usher syndrome type 1 and 2. *Vision Res*. 2012;75:60–70.
- Gorovoy IR, Gallagher DS, Eller AW, Mayercik VA, Friberg TR, Schuman JS. Cystoid macular edema in retinitis pigmentosa patients without associated macular thickening. *Semin Ophthalmol*. 2013;28(2):79–83.

21. Hee MR, Puliafito CA, Wong C, Duker JS, Reichel E, Rutledge B, et al. Quantitative assessment of macular edema with optical coherence tomography. *Arch Ophthalmol*. 1995;113(8):1019–29.
22. Akram MU, Tariq A, Khan SA, Javed MY. Automated detection of exudates and macula for grading of diabetic macular edema. *Comput Methods Programs Biomed*. 2014;114(2):141–52.
23. Smith RJ, Berlin CI, Hejtmancik JF, Keats BJ, Kimberling WJ, Lewis RA, et al. Clinical diagnosis of the Usher syndromes. Usher Syndrome Consortium. *Am J Med Genet*. 1994;50(1):32–8.
24. Sliesoraityte I, Troeger E, Kurtenbach A, Wilke R, Zrenner E. Multimodal multidimensional imaging for visual system status assessment. *Conf Proc IEEE Eng Med Biol Soc*. 2010;2010:3001–4.
25. Hajali M, Fishman GA, Anderson RJ. The prevalence of cystoid macular oedema in retinitis pigmentosa patients determined by optical coherence tomography. *Br J Ophthalmol*. 2008;92(8):1065–8.
26. Hajali M, Fishman GA. The prevalence of cystoid macular oedema on optical coherence tomography in retinitis pigmentosa patients without cystic changes on fundus examination. *Eye (Lond)*. 2009;23(4):915–9.
27. Heckenlively JR, Jordan BL, Aptsiauri N. Association of antiretinal antibodies and cystoid macular edema in patients with retinitis pigmentosa. *Am J Ophthalmol*. 1999;127:565–73.
28. Spalton DJ, Rahi AH, Bird AC. Immunological studies in retinitis pigmentosa associated with retinal vascular leakage. *Br J Ophthalmol*. 1978;62:183–7.
29. Bringmann A, Wiedemann P. Muller glial cells in retinal disease. *Ophthalmologica*. 2012;227:1–19.
30. Cunha-Vaz JG. The blood-retinal barriers system. Basic concepts and clinical evaluation. *Exp Eye Res*. 2004;78:715–21.
31. Grover S, Apushkin MA, Fishman GA. Topical dorzolamide for the treatment of cystoid macular edema in patients with retinitis pigmentosa. *Am J Ophthalmol*. 2006;141:850–8.
32. Liew G, Moore AT, Webster AR, Michaelides M. Efficacy and prognostic factors of response to carbonic anhydrase inhibitors in management of cystoid macular edema in retinitis pigmentosa. *Invest Ophthalmol Vis Sci*. 2015;56(3):1531–6.
33. Yanoff M, Fine BS, Brucker AJ, Eagle Jr RC. Pathology of human cystoid macular edema. *Surv Ophthalmol*. 1984;28:505–11.
34. Marmor MF. Mechanisms of fluid accumulation in retinal edema. *Doc Ophthalmol*. 1999;97:239–49.
35. Ganesh A, Stroh E, Manayath GJ, Al-Zuhaibi S, Levin AV. Macular cysts in retinal dystrophy. *Curr Opin Ophthalmol*. 2011;22(5):332–9.
36. Stanga PE, Downes SM, Ahuja RM, Chong NH, Antcliff R, Reck AC, et al. Comparison of optical coherence tomography and fluorescein angiography in assessing macular edema in retinal dystrophies: preliminary results. *Int Ophthalmol*. 2001;23(4–6):321–5.
37. Oishi A, Nakamura H, Tatsumi I, Sasahara M, Kojima H, Kurimoto M, et al. Optical coherence tomographic pattern and focal electroretinogram in patients with retinitis pigmentosa. *Eye (Lond)*. 2009;23(2):299–303.
38. Sandberg MA, Rosner B, Weigel-DiFranco C, McGee TL, Dryja TP, Berson EL. Disease course in patients with autosomal recessive retinitis pigmentosa due to the USH2A gene. *Invest Ophthalmol Vis Sci*. 2008;49(12):5532–9.
39. Kim YJ, Joe SG, Lee DH, Lee JY, Kim JG, Yoon YH. Correlations between spectral-domain OCT measurements and visual acuity in cystoid macular edema associated with retinitis pigmentosa. *Invest Ophthalmol Vis Sci*. 2013;54(2):1303–9.
40. Sliesoraityte I, Troeger E, Bernd A, Kurtenbach A, Zrenner E. Correlation between spectral domain OCT retinal nerve fibre layer thickness and multifocal pattern electroretinogram in advanced retinitis pigmentosa. *Adv Exp Med Biol*. 2012;723:471–8.

Submit your next manuscript to BioMed Central and we will help you at every step:

- We accept pre-submission inquiries
- Our selector tool helps you to find the most relevant journal
- We provide round the clock customer support
- Convenient online submission
- Thorough peer review
- Inclusion in PubMed and all major indexing services
- Maximum visibility for your research

Submit your manuscript at
www.biomedcentral.com/submit

